I 
115TH CONGRESS 
2D SESSION 
H. R. 5333 
To amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory 
framework with respect to certain nonprescription drugs that are mar-
keted without an approved new drug application, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 19, 2018 
Mr. LATTA (for himself, Mr. BURGESS, Mr. GENE GREEN of Texas, Ms. 
DEGETTE, Mr. GUTHRIE, and Mrs. DINGELL) introduced the following 
bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
clarify the regulatory framework with respect to certain 
nonprescription drugs that are marketed without an ap-
proved new drug application, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Over-the-Counter 
Monograph Safety, Innovation, and Reform Act of 2018’’. 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
TITLE I—OTC DRUG REVIEW 
SEC. 101. REGULATION OF CERTAIN NONPRESCRIPTION 
DRUGS THAT ARE MARKETED WITHOUT AN 
APPROVED NEW DRUG APPLICATION. 
(a) IN GENERAL.—Chapter V of the Federal Food, 
Drug, and Cosmetic Act is amended by inserting after sec-
tion 505F of such Act (21 U.S.C. 355g) the following: 
‘‘SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION 
DRUGS THAT ARE MARKETED WITHOUT AN 
APPROVED NEW DRUG APPLICATION. 
‘‘(a) NONPRESCRIPTION DRUGS MARKETED WITH-
OUT
AN
APPROVED
APPLICATION.—Nonprescription 
drugs marketed without an approved new drug application 
under section 505, as of the date of the enactment of the 
Over-the-Counter Monograph Safety, Innovation, and Re-
form Act of 2018, shall be treated in accordance with this 
subsection. 
‘‘(1) DRUGS SUBJECT TO A FINAL MONOGRAPH; 
CATEGORY
I
DRUGS
SUBJECT
TO
A
TENTATIVE 
FINAL MONOGRAPH.—A drug is deemed to be gen-
erally recognized as safe and effective within the 
meaning of section 201(p)(1), not a new drug under 
section 201(p), and not subject to section 503(b)(1), 
if— 
‘‘(A) the drug is— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) in conformity with the require-
ments for nonprescription use of a final 
monograph issued under part 330 of title 
21, Code of Federal Regulations (except as 
provided in paragraph (6)), the general re-
quirements for nonprescription drugs, and 
requirements under subsections (b), (c), 
and (k); and 
‘‘(ii) except as permitted by an order 
issued under subsection (b) or, in the case 
of a minor change in the drug, in con-
formity with an order issued under sub-
section (c), in a dosage form that, imme-
diately prior to the date of the enactment 
of this section, has been used to a material 
extent and for a material time within the 
meaning of section 201(p)(2); or 
‘‘(B) the drug is— 
‘‘(i) classified in category I for safety 
and effectiveness under a tentative final 
monograph that is the most recently appli-
cable proposal or determination issued 
under part 330 of title 21, Code of Federal 
Regulations; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) in conformity with the proposed 
requirements for nonprescription use of 
such tentative final monograph, any appli-
cable subsequent determination by the Sec-
retary, the general requirements for non-
prescription drugs, and requirements under 
subsections (b), (c), and (k); and 
‘‘(iii) except as permitted an order 
issued under subsection (b) or, in the case 
of a minor change in the drug, in con-
formity with an order issued under sub-
section (c), in a dosage form that, imme-
diately prior to the date of the enactment 
of this section, has been used to a material 
extent and for a material time within the 
meaning of section 201(p)(2). 
‘‘(2) TREATMENT
OF
SUNSCREEN
DRUGS.— 
With respect to sunscreen drugs subject to this sec-
tion, the applicable requirements shall be those set 
out at part 352 of title 21, Code of Federal Regula-
tions, as published at volume 64 page 27687 of the 
Federal Register, except that the applicable require-
ments governing effectiveness and labeling shall be 
those specified in section 201.327 of title 21, Code 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
of Federal Regulations, subject to the requirements 
of subsections (b), (c), and (k)(2). 
‘‘(3) CATEGORY III DRUGS SUBJECT TO A TEN-
TATIVE
FINAL
MONOGRAPH; CATEGORY
I
DRUGS 
SUBJECT TO PROPOSED MONOGRAPH OR ADVANCE 
NOTICE OF PROPOSED RULEMAKING.—A drug that 
is not described in paragraphs (1), (2), or (4) is not 
required to be the subject of an application approved 
under section 505, and is not subject to section 
503(b)(1), if— 
‘‘(A) the drug is— 
‘‘(i) classified in category III for safe-
ty or effectiveness in the preamble of a 
proposed rule establishing a tentative final 
monograph that is the most recently appli-
cable proposal or determination for such 
drug issued under part 330 of title 21, 
Code of Federal Regulations; 
‘‘(ii) in conformity with— 
‘‘(I) the conditions of use, includ-
ing indication and dosage strength, if 
any, described for such category III 
drug in such preamble or in an appli-
cable subsequent proposed rule; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(II) the proposed requirements 
for drugs classified in such tentative 
final monograph in category I in the 
most recently proposed rule estab-
lishing requirements related to such 
tentative final monograph and in any 
final rule establishing requirements 
that are applicable to the drug; and 
‘‘(III) the general requirements 
for nonprescription drugs and require-
ments under subsections (b) or (k); 
and 
‘‘(iii) in a dosage form that, imme-
diately prior to the date of the enactment 
of this section, was not required to have 
satisfied 
the 
requirements 
of 
section 
330.14 of title 21, Code of Federal Regula-
tions (as in effect at that time), in order 
for such drug to be lawfully marketed 
without an application approved under sec-
tion 505; or 
‘‘(B) the drug is— 
‘‘(i) classified in category I for safety 
and effectiveness under a proposed mono-
graph or advance notice of proposed rule-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
making that is the most recently applicable 
proposal or determination for such drug 
issued under part 330 of title 21, Code of 
Federal Regulations; 
‘‘(ii) in conformity with the require-
ments for nonprescription use of such pro-
posed monograph or advance notice of pro-
posed rulemaking, any applicable subse-
quent determination by the Secretary, the 
general requirements for nonprescription 
drugs, and requirements under subsections 
(b) or (k); and 
‘‘(iii) in a dosage form that, imme-
diately prior to the date of the enactment 
of this section, has been used to a material 
extent and for a material time within the 
meaning of section 201(p)(2). 
‘‘(4) CATEGORY
II
DRUGS
DEEMED
NEW 
DRUGS.—A drug that is classified in category II for 
safety or effectiveness under a tentative final mono-
graph or that is subject to a determination to be not 
safe or effective in a proposed rule that is the most 
recently applicable proposal issued under part 330 of 
title 21, Code of Federal Regulations, shall be 
deemed to be a new drug within the meaning of sec-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
tion 201(p), misbranded under section 502(ee), and 
subject to the requirement for an approved new drug 
application under section 505 beginning on the day 
that is 180 calendar days after the date of the en-
actment of this section, unless, before such day, the 
Secretary determines that it is in the interest of 
public health to extend the period during which the 
drug may be marketed without such an approved 
new drug application. 
‘‘(5) 
DRUGS
NOT
GRASE
DEEMED
NEW 
DRUGS.—A drug that the Secretary has determined 
not to be generally recognized as safe and effective 
within the meaning of section 201(p)(1) under a 
final determination issued under part 330 of title 
21, Code of Federal Regulations, shall be deemed to 
be a new drug within the meaning of section 201(p), 
misbranded under section 502(ee), and subject to 
the requirement for an approved new drug applica-
tion under section 505. 
‘‘(6) OTHER DRUGS DEEMED NEW DRUGS.— 
Except as provided in subsection (m), a drug is 
deemed to be a new drug within the meaning of sec-
tion 201(p) and misbranded under section 502(ee) if 
the drug— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(A) is not subject to section 503(b)(1); 
and 
‘‘(B) is not described in paragraphs (1), 
(2), (3), (4), or (5), or subsection (b)(1)(B). 
‘‘(b) ADMINISTRATIVE ORDERS.— 
‘‘(1) IN GENERAL.— 
‘‘(A) 
DETERMINATION.—The 
Secretary 
may, on the initiative of the Secretary or at the 
request of one or more requestors, issue admin-
istrative orders determining whether there are 
conditions under which specific drugs, classes of 
such drugs, or combinations of such drugs are 
determined to be— 
‘‘(i) not subject to section 503(b)(1); 
and 
‘‘(ii) generally recognized as safe and 
effective within the meaning of section 
201(p)(1). 
‘‘(B) EFFECT.—A drug or combination of 
drugs shall be deemed to not require approval 
under section 505 if such drug or combination 
of drugs— 
‘‘(i) is determined by the Secretary to 
meet the conditions specified in clauses (i) 
and (ii) of subparagraph (A); 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) is marketed in conformity with 
an administrative order under this sub-
section; 
‘‘(iii) meets the general requirements 
for nonprescription drugs; and 
‘‘(iv) meets the requirements specified 
in subsections (c) and (k). 
‘‘(C) STANDARD.—The Secretary shall find 
that a drug is not generally recognized as safe 
and effective within the meaning of section 
201(p)(1) if— 
‘‘(i) the evidence shows that the drug 
is not generally recognized as safe and ef-
fective within the meaning of section 
201(p)(1); or 
‘‘(ii) the evidence is inadequate to 
show that the drug is generally recognized 
as safe and effective within the meaning of 
section 201(p)(1). 
‘‘(2) ADMINISTRATIVE
ORDERS
INITIATED
BY 
THE SECRETARY.— 
‘‘(A) IN GENERAL.—In issuing an adminis-
trative order under paragraph (1) upon the 
Secretary’s initiative, the Secretary shall— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) make reasonable efforts to notify 
informally, not later than 2 business days 
before the issuance of the proposed order, 
sponsors of drugs that will be subject to 
the administrative order; 
‘‘(ii) after any such reasonable efforts 
of notification— 
‘‘(I) issue a proposed administra-
tive order by publishing it on the 
website of the Food and Drug Admin-
istration and include in such order the 
reasons for the issuance of such order; 
and 
‘‘(II) publish a notice of avail-
ability of such proposed order in the 
Federal Register; 
‘‘(iii) except as provided in subpara-
graph (B), provide for a public comment 
period with respect to such proposed order 
of not less than 45 calendar days; and 
‘‘(iv) if, after completion of the pro-
ceedings specified in clauses (i) through 
(iii), the Secretary determines that it is ap-
propriate to issue a final administrative 
order— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(I) issue the final administrative 
order, together with a detailed state-
ment of reasons, which order shall not 
take effect until the time for request-
ing judicial review under paragraph 
(3)(D)(ii) has expired; 
‘‘(II) publish a notice of such 
final administrative order in the Fed-
eral Register; 
‘‘(III) afford requestors of drugs 
that will be subject to such order the 
opportunity for formal dispute resolu-
tion up to the level of the Director of 
the Center for Drug Evaluation and 
Research, which initially must be re-
quested within 45 calendar days of 
the issuance of the order, and, for 
subsequent levels of appeal, within 30 
calendar days of the prior decision; 
and 
‘‘(IV) except with respect to 
drugs described in paragraph (3)(B), 
upon completion of the formal dispute 
resolution procedure, inform the per-
sons which sought such dispute reso-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
lution of their right to request a hear-
ing. 
‘‘(B) EXCEPTIONS.—When issuing an ad-
ministrative order under paragraph (1) on the 
Secretary’s initiative proposing to determine 
that a drug described in subsection (a)(3) is not 
generally recognized as safe and effective within 
the meaning of section 201(p)(1), the Secretary 
shall follow the procedures in subparagraph 
(A), except that— 
‘‘(i) the proposed order shall include 
notice of— 
‘‘(I) the general categories of 
data the Secretary has determined 
necessary to establish that the drug is 
generally recognized as safe and effec-
tive within the meaning of section 
201(p)(1); and 
‘‘(II) the format for submissions 
by interested persons; 
‘‘(ii) the Secretary shall provide for a 
public comment period of no less than 180 
calendar days with respect to such pro-
posed order, except when the Secretary de-
termines, for good cause, that a shorter pe-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
riod is in the interests of public health; 
and 
‘‘(iii) any person who submits data in 
such comment period shall include a cer-
tification that the person has submitted all 
evidence created, obtained, or received by 
that person that is both within the cat-
egories of data identified in the proposed 
order and relevant to a determination as to 
whether the drug is generally recognized as 
safe and effective within the meaning of 
section 201(p)(1). 
‘‘(3) HEARINGS; JUDICIAL REVIEW.— 
‘‘(A) IN
GENERAL.—Only a person who 
participated in each stage of formal dispute res-
olution under subclause (III) of paragraph 
(2)(A)(iv) of an administrative order with re-
spect to a drug may request a hearing con-
cerning a final administrative order issued 
under such paragraph with respect to such 
drug. Such person must submit a request for a 
hearing, which shall be based solely on informa-
tion in the administrative record, to the Sec-
retary not later than 30 calendar days after re-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
ceiving notice of the final decision of the formal 
dispute resolution procedure. 
‘‘(B) NO
HEARING
REQUIRED
WITH
RE-
SPECT
TO
ORDERS
RELATING
TO
CERTAIN 
DRUGS.— 
‘‘(i) IN
GENERAL.—The Secretary 
shall not be required to provide notice and 
an opportunity for a hearing pursuant to 
paragraph (2)(A)(iv) if the final adminis-
trative order involved relates to a drug— 
‘‘(I) that is described in sub-
section (a)(3)(A); and 
‘‘(II) with respect to which no 
human or non-human data studies rel-
evant to the safety or effectiveness of 
such drug have been submitted to the 
administrative 
record 
since 
the 
issuance of the most recent tentative 
final monograph relating to such 
drug. 
‘‘(ii) HUMAN
DATA
STUDIES
AND 
NON-HUMAN DATA DEFINED.—In this sub-
paragraph: 
‘‘(I) The term ‘human data stud-
ies’ means clinical trials of safety or 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
effectiveness (including actual use 
studies), pharmacokinetics studies, or 
bioavailability studies. 
‘‘(II) The term ‘non-human data’ 
means data from testing other than 
with human subjects which provides 
information concerning safety or ef-
fectiveness. 
‘‘(C) HEARING PROCEDURES.— 
‘‘(i) DENIAL OF REQUEST FOR HEAR-
ING.—If the Secretary determines that in-
formation submitted in a request for a 
hearing under subparagraph (A) with re-
spect to a final administrative order issued 
under paragraph (2)(A)(iv), does not iden-
tify the existence of a genuine and sub-
stantial question of material fact, the Sec-
retary may deny such request. In making 
such a determination, the Secretary may 
consider only information and data that 
are based on relevant and reliable scientific 
principles and methodologies. 
‘‘(ii) SINGLE HEARING FOR MULTIPLE 
RELATED
REQUESTS.—If more than one 
request for a hearing is submitted with re-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
spect to the same administrative order 
under subparagraph (A), the Secretary 
may direct that a single hearing be con-
ducted in which all persons whose hearing 
requests were granted may participate. 
‘‘(iii) PRESIDING OFFICER.—The pre-
siding officer of a hearing requested under 
subparagraph (A) shall— 
‘‘(I) be designated by the Sec-
retary; 
‘‘(II) not be an employee of the 
Center for Drug Evaluation and Re-
search; and 
‘‘(III) not have been previously 
involved in the development of the ad-
ministrative order involved or pro-
ceedings relating to that administra-
tive order. 
‘‘(iv) RIGHTS OF PARTIES TO HEAR-
ING.—The parties to a hearing requested 
under subparagraph (A) shall have the 
right to present testimony, including testi-
mony of expert witnesses, and to cross-ex-
amine witnesses presented by other parties. 
Where appropriate, the presiding officer 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
may require that cross-examination by par-
ties representing substantially the same in-
terests be consolidated to promote effi-
ciency and avoid duplication. 
‘‘(v) FINAL DECISION.— 
‘‘(I) At the conclusion of a hear-
ing requested under subparagraph 
(A), the presiding officer of the hear-
ing shall issue a decision containing 
findings of fact and conclusions of 
law. The decision of the presiding offi-
cer shall be final. 
‘‘(II) The final decision may not 
take effect until the period under sub-
paragraph (D)(ii) for submitting a re-
quest for judicial review of such deci-
sion expires. 
‘‘(D) JUDICIAL REVIEW OF FINAL ADMIN-
ISTRATIVE ORDER.— 
‘‘(i) IN
GENERAL.—The procedures 
described in section 505(h) shall apply 
with respect to judicial review of final ad-
ministrative orders issued under this sub-
section in the same manner and to the 
same extent as such section applies to an 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
order described in such section except that 
the judicial review shall be taken by filing 
in an appropriate district court of the 
United States in lieu of the appellate 
courts specified in such section. 
‘‘(ii) PERIOD TO SUBMIT A REQUEST 
FOR JUDICIAL REVIEW.—A person eligible 
to request a hearing under this paragraph 
and seeking judicial review of a final ad-
ministrative order issued under this sub-
section shall file such request for judicial 
review not later than 60 calendar days 
after the latest of— 
‘‘(I) the date on which notice of 
such order is published; 
‘‘(II) the date on which a hearing 
with respect to such order is denied 
under subparagraph (B) or (C)(i); 
‘‘(III) the date on which a final 
decision is made following a hearing 
under subparagraph (C)(v); or 
‘‘(IV) if no hearing is requested, 
the date on which the time for re-
questing a hearing expires. 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(4) EXPEDITED PROCEDURE WITH RESPECT 
TO
ADMINISTRATIVE
ORDERS
INITIATED
BY
THE 
SECRETARY.— 
‘‘(A) IMMINENT HAZARD TO THE PUBLIC 
HEALTH.— 
‘‘(i) IN GENERAL.—In the case of a 
determination by the Secretary that a 
drug, class of drugs, or combination of 
drugs subject to this section poses an im-
minent hazard to the public health, the 
Secretary, after first making reasonable ef-
forts to notify, not later than 48 hours be-
fore issuance of such order under this sub-
paragraph, sponsors who have a listing in 
effect under section 510(j) for such drug 
or combination of drugs— 
‘‘(I) may issue an interim final 
administrative order for such drug, 
class of drugs, or combination of 
drugs under paragraph (1), together 
with a detailed statement of the rea-
sons for such order; 
‘‘(II) shall publish in the Federal 
Register a notice of availability of any 
such order; and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(III) shall provide for a public 
comment period of at least 45 cal-
endar days with respect to such in-
terim final order. 
‘‘(ii) 
NONDELEGATION.—The 
Sec-
retary may not delegate the authority to 
issue an interim final administrative order 
under this subparagraph. 
‘‘(B) SAFETY LABELING CHANGES.— 
‘‘(i) IN GENERAL.—In the case of a 
determination by the Secretary that a 
change in the labeling of a drug, class of 
drugs, or combination of drugs subject to 
this section is reasonably expected to miti-
gate a significant or unreasonable risk of 
a serious adverse event associated with use 
of the drug, the Secretary may— 
‘‘(I) make reasonable efforts to 
notify informally, not later than 48 
hours before the issuance of the in-
terim final order, the sponsors of 
drugs who have a listing in effect 
under section 510(j) for such drug or 
combination of drugs; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(II) after reasonable efforts of 
notification, issue an interim final ad-
ministrative order in accordance with 
paragraph (1) to require such change, 
together with a detailed statement of 
the reasons for such order; 
‘‘(III) publish in the Federal 
Register a notice of availability of 
such order; and 
‘‘(IV) provide for a public com-
ment period of at least 45 calendar 
days with respect to such interim final 
order. 
‘‘(ii) CONTENT
OF
ORDER.—An in-
terim final order issued under this sub-
paragraph with respect to the labeling of a 
drug may provide for new warnings and 
other information required for safe use of 
the drug. 
‘‘(C) EFFECTIVE DATE.—An order under 
subparagraph (A) or (B) shall take effect on a 
date specified by the Secretary. 
‘‘(D) FINAL ORDER.—After the completion 
of the proceedings in subparagraph (A) or (B), 
the Secretary shall— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) issue a final order in accordance 
with paragraph (1); 
‘‘(ii) publish a notice of availability of 
such final administrative order in the Fed-
eral Register; and 
‘‘(iii) afford sponsors of such drugs 
that will be subject to such an order the 
opportunity for formal dispute resolution 
up to the level of the Director of the Cen-
ter for Drug Evaluation and Research, 
which must initially be within 45 calendar 
days of the issuance of the order, and for 
subsequent levels of appeal, within 30 cal-
endar days of the prior decision. 
‘‘(E) HEARINGS.—A sponsor of a drug 
subject to a final order issued under subpara-
graph (D) and that participated in each stage 
of formal dispute resolution under clause (iii) of 
such subparagraph may request a hearing on 
such order. The provisions of subparagraphs 
(A), (B), and (C) of paragraph (3), other than 
paragraph (3)(C)(v)(II), shall apply with re-
spect to a hearing on such order in the same 
manner and to the same extent as such provi-
sions apply with respect to a hearing on an ad-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
ministrative order issued under paragraph 
(2)(A)(iv). 
‘‘(F) TIMING.—Not later than 12 months 
after the date on which an interim final order 
is issued under subparagraph (A) or (B), the 
Secretary shall issue a final order in accordance 
with paragraph (1) and complete any required 
hearing. 
‘‘(G) JUDICIAL
REVIEW.—A final order 
issued pursuant to subparagraph (F) shall be 
subject to judicial review in accordance with 
paragraph (3)(D). 
‘‘(5) ADMINISTRATIVE
ORDER
INITIATED
AT 
THE REQUEST OF A REQUESTOR.— 
‘‘(A) IN GENERAL.—In issuing an adminis-
trative order under paragraph (1) at the re-
quest of a requestor with respect to certain 
drugs, classes of drugs, or combinations of 
drugs— 
‘‘(i) the Secretary shall, after receiv-
ing a request under this subparagraph, de-
termine whether the request is sufficiently 
complete and formatted to permit a sub-
stantive review; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) if the Secretary determines that 
the request is sufficiently complete and for-
matted to permit a substantive review, the 
Secretary shall— 
‘‘(I) file the request; and 
‘‘(II) initiate proceedings with re-
spect to issuing an administrative 
order in accordance with paragraphs 
(2) and (3); and 
‘‘(iii) except as provided in paragraph 
(6), if the Secretary determines that a re-
quest does not meet the requirements for 
filing or is not sufficiently complete and 
formatted to permit a substantive review, 
the requestor may demand that the request 
be filed over protest, and the Secretary 
shall initiate proceedings to review the re-
quest in accordance with paragraph (2)(A). 
‘‘(B) 
REQUEST
TO
INITIATE
PRO-
CEEDINGS.— 
‘‘(i) IN GENERAL.—A requestor seek-
ing an administrative order under para-
graph (1) with respect to certain drugs, 
classes of drugs, or combinations of drugs, 
shall submit to the Secretary a request to 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
initiate proceedings for such order in the 
form and manner as specified by the Sec-
retary. Such requestor may submit a re-
quest under this subparagraph for the 
issuance of an administrative order— 
‘‘(I) determining whether a drug 
is generally recognized as safe and ef-
fective within the meaning of section 
201(p)(1), 
exempt 
from 
section 
503(b)(1), and not required to be the 
subject of an approved application 
under section 505; or 
‘‘(II) 
determining 
whether 
a 
change to a condition of use of a drug 
is generally recognized as safe and ef-
fective within the meaning of section 
201(p)(1), 
exempt 
from 
section 
503(b)(1), and not required to be the 
subject of an approved application 
under section 505, if such drug is— 
‘‘(aa) absent such a changed 
condition of use, generally recog-
nized as safe and effective within 
the meaning of section 201(p)(1) 
in accordance with subsection 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
(a)(1), (a)(2), or an order under 
this subsection; or 
‘‘(bb) subject to subsection 
(a)(3), but only if such requestor 
initiates such request in conjunc-
tion with a request for the Sec-
retary to determine whether such 
drug is generally recognized as 
safe and effective within the 
meaning of section 201(p)(1), 
which is filed by the Secretary 
under subparagraph (A)(ii). 
‘‘(ii) EXCEPTION.—The Secretary is 
not required to complete review of a re-
quest for a change described in clause 
(i)(II) if the Secretary determines that 
there is an inadequate basis to find the 
drug is generally recognized as safe and ef-
fective within the meaning of section 
201(p)(1) under paragraph (1) and issues 
a final order announcing that determina-
tion. 
‘‘(iii) WITHDRAWAL.—The requestor 
may withdraw a request under this para-
graph, according to the procedures set 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
forth pursuant to subsection (d)(2)(B). 
Notwithstanding any other provision of 
this section, if such request is withdrawn, 
the Secretary may cease proceedings under 
this subparagraph. 
‘‘(C) EXCLUSIVITY.— 
‘‘(i) IN GENERAL.—A final adminis-
trative order issued in response to a re-
quest under this section shall have the ef-
fect of authorizing solely the order re-
questor (or the licensees, assignees, or suc-
cessors in interest of such requestor with 
respect to the subject of such order), for a 
period of 18 months following the effective 
date of such final order, to market drugs— 
‘‘(I) incorporating changes de-
scribed in clause (ii); 
‘‘(II) beginning on the date the 
requestor (or any such licensees, as-
signees, or successors in interest) may 
lawfully market such drugs pursuant 
to the order; and 
‘‘(III) subject to the limitations 
under clause (iv). 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) 
CHANGES
DESCRIBED.—A 
change described in this clause is a change 
subject to an order specified in clause (i), 
which— 
‘‘(I) provides for a drug to con-
tain an active ingredient (including 
any ester or salt of the active ingre-
dient) not previously incorporated in a 
drug described in clause (iii); or 
‘‘(II) provides for a change in the 
conditions of use of a drug, for which 
new human data studies conducted or 
sponsored by the requestor (or for 
which the requestor has an exclusive 
right of reference) were essential to 
the issuance of such order. 
‘‘(iii) DRUGS DESCRIBED.—The drugs 
described in this clause are drugs— 
‘‘(I) 
specified 
in 
subsection 
(a)(1), (a)(2), or (a)(3); 
‘‘(II) subject to a final order 
issued under this section; 
‘‘(III) subject to a final sun-
screen order (as defined in section 
586(2)(A)); or 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(IV) described in subsection 
(m)(1), other than drugs subject to an 
active enforcement action under chap-
ter III of this Act. 
‘‘(iv) 
LIMITATIONS
ON
EXCLU-
SIVITY.— 
‘‘(I) IN GENERAL.—Only one pe-
riod of exclusivity shall be granted, 
under each order described in clause 
(i), with respect to changes (to the 
drug subject to such order) which are 
either— 
‘‘(aa) changes described in 
clause (ii)(I), relating to active 
ingredients; or 
‘‘(bb) changes described in 
clause (ii)(II), relating to condi-
tions of use. 
‘‘(II) 
NO
EXCLUSIVITY
AL-
LOWED.—No exclusivity shall apply to 
changes to a drug which are— 
‘‘(aa) the subject of a Tier 2 
OTC monograph order request 
(as defined in section 744N); 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(bb) safety-related changes, 
as defined by the Secretary, or 
any other changes the Secretary 
considers necessary to assure 
safe use; or 
‘‘(cc) changes related to 
methods of testing safety or effi-
cacy. 
‘‘(v) NEW HUMAN DATA STUDIES DE-
FINED.—In this subparagraph, the term 
‘new human data studies’ means clinical 
trials of safety or effectiveness (including 
actual use studies), pharmacokinetics stud-
ies, or bioavailability studies, the results of 
which— 
‘‘(I) have not been relied on by 
the Secretary to support— 
‘‘(aa) a proposed or final de-
termination that a drug described 
in subclauses (I), (II), or (III) of 
clause (iii) is generally recognized 
as safe and effective within the 
meaning of section 201(p)(1); or 
‘‘(bb) approval of a drug 
that was approved under section 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
505 (except for an approval 
changing a drug from prescrip-
tion to nonprescription status); 
and 
‘‘(II) do not duplicate the results 
of another study that was relied on by 
the Secretary to support— 
‘‘(aa) a proposed or final de-
termination that a drug described 
in subclauses (I), (II), or (III) of 
clause (iii) is generally recognized 
as safe and effective within the 
meaning of section 201(p)(1); or 
‘‘(bb) approval of a drug 
that was approved under section 
505 (except for an approval 
changing a drug from prescrip-
tion to nonprescription status). 
‘‘(vi) 
EFFECTIVE
DATE.—A 
final 
order subject to clause (i) shall take effect 
on the date when the order requestor (or 
the licensees, assignees, or successors in 
interest of such requestor with respect to 
such order) submits updated drug listing 
information under subsection (e) with re-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
spect to the change which is permitted 
under such order. 
‘‘(6) INFORMATION
REGARDING
SAFE
NON-
PRESCRIPTION MARKETING AND USE AS CONDITION 
FOR FILING A GENERALLY RECOGNIZED AS SAFE 
AND EFFECTIVE REQUEST.— 
‘‘(A) IN GENERAL.—In response to a re-
quest under this section that a drug described 
in subparagraph (B) be generally recognized as 
safe and effective, the Secretary— 
‘‘(i) may file such request, if the re-
quest includes information specified under 
subparagraph (C) with respect to safe non-
prescription marketing and use of such 
drug; or 
‘‘(ii) if the request fails to include in-
formation specified under subparagraph 
(C), shall refuse to file such request and 
require that nonprescription marketing of 
the drug be pursuant to a new drug appli-
cation as described in subparagraph (D). 
‘‘(B) DRUG
DESCRIBED.—A drug de-
scribed in this subparagraph is a nonprescrip-
tion drug which contains an active ingredient 
not previously incorporated in a drug— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) specified in subsection (a)(1), 
(a)(2), or (a)(3); 
‘‘(ii) subject to a final order under 
this section; or 
‘‘(iii) subject to a final sunscreen 
order (as defined in section 586(2)(A)). 
‘‘(C) 
INFORMATION
DEMONSTRATING 
PRIMA
FACIE
SAFE
NONPRESCRIPTION
MAR-
KETING
AND
USE.—Information specified in 
this subparagraph, with respect to a request de-
scribed in subparagraph (A)(i), is— 
‘‘(i) information sufficient for a prima 
facie demonstration that the drug subject 
to such request has a verifiable history of 
being marketed and safely used by con-
sumers in the United States as a non-
prescription drug under comparable condi-
tions of use; 
‘‘(ii) if the drug has not been pre-
viously marketed in the United States as a 
nonprescription drug, information suffi-
cient for a prima facie demonstration that 
the drug was marketed and safely used 
under comparable conditions of marketing 
and use in a country listed in section 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00034
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
802(b)(1)(A) or designated by the Sec-
retary 
in 
accordance 
with 
section 
802(b)(1)(B)— 
‘‘(I) for such period of time as 
needed to provide reasonable assur-
ances concerning the safe nonprescrip-
tion use of the drug; and 
‘‘(II) during such time was sub-
ject to sufficient monitoring by a reg-
ulatory body considered acceptable by 
the Secretary for such monitoring 
purposes, including for adverse events 
associated with nonprescription use of 
the drug; or 
‘‘(iii) if the Secretary determines that 
information described in clauses (i) or (ii) 
is not needed to provide a prima facie dem-
onstration that the drug can be safely mar-
keted and used as a nonprescription drug, 
such other information the Secretary deter-
mines is sufficient for such purposes. 
‘‘(D) MARKETING
PURSUANT
TO
NEW 
DRUG APPLICATION.—In the case of a request 
described in subparagraph (A)(ii), the drug 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00035
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
subject to such request may be re-submitted for 
filing only if— 
‘‘(i) the drug is marketed as a non-
prescription drug, under conditions of use 
comparable to the conditions specified in 
the request, for such period of time as the 
Secretary determines appropriate (not to 
exceed five consecutive years) pursuant to 
an application approved under section 505; 
and 
‘‘(ii) during such time period, one mil-
lion retail packages of the drug, or an 
equivalent quantity as determined by the 
Secretary, were distributed for retail sale, 
as determined in such manner as the Sec-
retary finds appropriate. 
‘‘(E) RULE OF APPLICATION.—Except in 
the case of a request involving a drug described 
in section 586(9), as in effect on January 1, 
2017, if the Secretary refuses to file a request 
under this paragraph, the requestor may not 
file such request over protest under paragraph 
(5)(A)(iii). 
‘‘(7) PACKAGING.—An administrative order 
issued under paragraph (2), (4)(A), or (5) may in-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00036
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
clude requirements for the packaging of a drug to 
encourage use in accordance with labeling. Such re-
quirements may include unit dose packaging, re-
quirements for products intended for use by chil-
dren, requirements to reduce risk of harm from un-
supervised ingestion, and other appropriate require-
ments. This paragraph does not authorize the Food 
and Drug Administration to require standards or 
testing procedures as described in part 1700 of title 
16, Code of Federal Regulations. 
‘‘(8) FINAL
AND
TENTATIVE
FINAL
MONO-
GRAPHS FOR CATEGORY I DRUGS DEEMED FINAL 
ADMINISTRATIVE ORDERS.— 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (B), a final monograph or tentative final 
monograph establishing conditions of use for a 
drug described in subsection (a)(1), shall be 
deemed to be a final administrative order under 
this subsection and may be amended, revoked, 
or otherwise modified in accordance with the 
procedures of this subsection. 
‘‘(B) DEEMED ORDERS INCLUDE HARMO-
NIZING
TECHNICAL
AMENDMENTS.—The 
deemed establishment of a final administrative 
order under subparagraph (A) shall be con-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
strued to include any technical amendments to 
such order as the Secretary determines nec-
essary to ensure that such order is appro-
priately harmonized, in terms of terminology or 
cross-references, with the applicable provisions 
of this Act (and regulations thereunder) and 
any other orders issued under this section. 
‘‘(c) PROCEDURE FOR MINOR CHANGES.— 
‘‘(1) IN GENERAL.—Minor changes in the dos-
age form of a drug that is described in paragraph 
(1) or (2) of subsection (a) or the subject of an 
order issued under subsection (b) may be made by 
a requestor without the issuance of an order under 
subsection (b) if— 
‘‘(A) the requestor maintains such infor-
mation as is necessary to demonstrate that the 
change— 
‘‘(i) will not affect the safety or effec-
tiveness of the drug; and 
‘‘(ii) will not materially affect the ex-
tent of absorption or other exposure to the 
active ingredient in comparison to a suit-
able reference product; and 
‘‘(B) the change is in conformity with the 
requirements of an applicable administrative 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
order issued by the Secretary under paragraph 
(3). 
‘‘(2) ADDITIONAL INFORMATION.— 
‘‘(A) ACCESS
TO
RECORDS.—A sponsor 
shall submit records requested by the Secretary 
relating to such a minor change under section 
704(a)(4), within 15 business days of receiving 
such a request, or such longer period as the 
Secretary may provide. 
‘‘(B) INSUFFICIENT INFORMATION.—If the 
Secretary determines that the information con-
tained in such records is not sufficient to dem-
onstrate that the change does not affect the 
safety or effectiveness of the drug or materially 
affect the extent of absorption or other expo-
sure to the active ingredient, the Secretary— 
‘‘(i) may so inform the sponsor of the 
drug in writing; and 
‘‘(ii) provide the sponsor of the drug 
with a reasonable opportunity to provide 
additional information. 
‘‘(C) FAILURE TO SUBMIT SUFFICIENT IN-
FORMATION.—If the sponsor fails to provide 
such additional information within the pre-
scribed time, or if the Secretary determines that 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
such additional information does not dem-
onstrate that the change does not affect the 
safety or effectiveness of the drug or materially 
affect the extent of absorption or other expo-
sure to the active ingredient, the drug as modi-
fied is a new drug within the meaning of sec-
tion 201(p) and shall be deemed to be mis-
branded under section 502(ee). 
‘‘(3) DETERMINING WHETHER A CHANGE WILL 
AFFECT SAFETY OR EFFECTIVENESS.— 
‘‘(A) IN
GENERAL.—The Secretary shall 
issue one or more administrative orders speci-
fying requirements for determining whether a 
minor change made by a sponsor pursuant to 
this subsection will affect the safety or effective-
ness of a drug or materially affect the extent of 
absorption or other exposure to an active ingre-
dient in the drug in comparison to a suitable 
reference product, together with guidance for 
applying those orders to specific dosage forms. 
‘‘(B) STANDARD PRACTICES.—The orders 
and guidance issued by the Secretary under 
subparagraph (A) shall take into account rel-
evant public standards and standard practices 
for evaluating the quality of drugs, and may 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
take into account the special needs of popu-
lations, including children. 
‘‘(d) CONFIDENTIALITY
OF
INFORMATION
SUB-
MITTED BY REQUESTORS.— 
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
any information, including reports of testing con-
ducted on the drug or drugs involved, that is sub-
mitted by a requestor in connection with proceedings 
on an order under this section (including any minor 
change under subsection (c)) and is a trade secret 
or confidential information subject to section 
552(b)(4) of title 5, United States Code, or section 
1905 of title 18, United States Code, shall not be 
disclosed to the public unless the requestor consents 
to that disclosure. 
‘‘(2) PUBLIC
AVAILABILITY.—Notwithstanding 
paragraph (1), the Secretary shall make available to 
the public any information (other than raw data 
sets) submitted by a requestor in support of a re-
quest under subsection (b)(5)(A) as of the date on 
which the proposed order is made public unless— 
‘‘(A) the information pertains to pharma-
ceutical quality information except to the extent 
that specific information is necessary to estab-
lish standards under which a drug is generally 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
recognized as safe and effective within the 
meaning of section 201(p)(1); 
‘‘(B) the information is submitted in a re-
questor-initiated request, but the requestor 
withdraws such request, in accordance with 
withdrawal procedures established by the Sec-
retary, before the Secretary issues the proposed 
order; or 
‘‘(C) the Secretary obtains the information 
under subsection (c). 
‘‘(e) UPDATES TO DRUG LISTING INFORMATION.— 
A sponsor who makes a change to a drug subject to this 
section shall submit updated drug listing information for 
the drug in accordance with section 510(j) within 30 cal-
endar days of the date when the drug is first commercially 
marketed, except that a sponsor who was the order re-
questor with respect to an order subject to subsection 
(b)(5)(C) (or a licensee, assignee, or successor in interest 
of such requestor) shall submit updated drug listing infor-
mation on or before the date when the drug is first com-
mercially marketed. 
‘‘(f) APPROVALS UNDER SECTION 505.—The provi-
sions of this section shall not be construed to preclude a 
person from seeking or maintaining the approval of a drug 
under sections 505(b)(1), 505(b)(2), and 505(j). A deter-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
mination under this section that a drug is not subject to 
section 503(b)(1), is generally recognized as safe and ef-
fective within the meaning of section 201(p)(1), and is not 
a new drug under section 201(p) shall constitute a finding 
that the drug is safe and effective that may be relied upon 
for purposes of an application under section 505(b)(2), so 
that the applicant shall be required to submit for purposes 
of such application only information needed to support any 
modification of the drug that is not covered by such deter-
mination under this section. 
‘‘(g) PUBLIC AVAILABILITY OF ADMINISTRATIVE OR-
DERS.—The Secretary shall establish, maintain, update 
(as determined necessary by the Secretary but no less fre-
quently than annually), and make publicly available, with 
respect to orders issued under this section— 
‘‘(1) a repository of each final order and in-
terim final order in effect, including the complete 
text of the order; and 
‘‘(2) a listing of all orders proposed and under 
development under subsection (b)(2), including— 
‘‘(A) a brief description of each such order; 
and 
‘‘(B) the Secretary’s expectations, if re-
sources permit, for issuance of proposed orders 
over a three-year period. 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(h) DEVELOPMENT ADVICE TO SPONSORS OR RE-
QUESTORS.—The Secretary shall establish procedures 
under which sponsors or requestors may meet with appro-
priate officials of the Food and Drug Administration to 
obtain advice on the studies and other information nec-
essary to support submissions under this section and other 
matters relevant to the regulation of nonprescription 
drugs and the development of new nonprescription drugs 
under this section. 
‘‘(i) PARTICIPATION OF MULTIPLE SPONSORS OR RE-
QUESTORS.—The Secretary shall establish procedures to 
facilitate efficient participation by multiple sponsors or re-
questors in proceedings under this section, including provi-
sion for joint meetings with multiple sponsors or reques-
tors or with organizations nominated by sponsors or re-
questors to represent their interests in a proceeding. 
‘‘(j) ELECTRONIC FORMAT.—All submissions under 
this section shall be in electronic format. 
‘‘(k) EFFECT
ON EXISTING REGULATIONS GOV-
ERNING NONPRESCRIPTION DRUGS.— 
‘‘(1) REGULATIONS
OF
GENERAL
APPLICA-
BILITY
TO
NONPRESCRIPTION
DRUGS.—Except as 
provided in this subsection, nothing in this section 
supersedes regulations establishing general require-
ments for nonprescription drugs, including regula-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00044
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
tions of general applicability contained in parts 201, 
250, and 330 of title 21, Code of Federal Regula-
tions, or any successor regulations. The Secretary 
shall establish or modify such regulations by means 
of rulemaking in accordance with section 553 of title 
5, United States Code. 
‘‘(2) REGULATIONS
ESTABLISHING
REQUIRE-
MENTS FOR SPECIFIC NONPRESCRIPTION DRUGS.— 
‘‘(A) The provisions of section 310.545 of 
title 21, Code of Federal Regulations, as in ef-
fect on the day before the date of the enact-
ment of this section, shall be deemed to be a 
final order under subsection (b). 
‘‘(B) Regulations in effect on the day be-
fore the date of the enactment of this section, 
establishing requirements for specific non-
prescription drugs marketed pursuant to this 
section (including such requirements in parts 
201 and 250 of title 21, Code of Federal Regu-
lations), shall be deemed to be final orders 
under subsection (b), only as they apply to 
drugs subject to paragraphs (1), (2), (3), and 
(6) of subsection (a). 
‘‘(3) WITHDRAWAL
OF
REGULATIONS.—The 
Secretary shall withdraw regulations establishing 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00045
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
final monographs and the procedures governing the 
over-the-counter drug review under part 330 and 
other relevant parts of title 21, Code of Federal 
Regulations (as in effect on the day before the date 
of the enactment of this section), or make technical 
changes to such regulations to ensure conformity 
with appropriate terminology and cross references. 
Notwithstanding subchapter II of chapter 5 of title 
5, United States Code, any such withdrawal or tech-
nical changes shall be made without public notice 
and comment and shall be effective upon publication 
through notice in the Federal Register (or upon such 
date as specified in such notice). 
‘‘(l) GUIDANCE.—The Secretary shall issue guidance 
that specifies— 
‘‘(1) the procedures and principles for formal 
meetings between the Secretary and sponsors or re-
questors for drugs subject to this section; 
‘‘(2) the format and content of data submis-
sions to the Secretary under this section; 
‘‘(3) the format of electronic submissions to the 
Secretary under this section; 
‘‘(4) consolidated proceedings and the proce-
dures for such proceedings where appropriate; and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00046
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(5) for minor changes in drugs, recommenda-
tions on how to comply with the requirements in or-
ders issued under subsection (c)(3). 
‘‘(m) RULE OF CONSTRUCTION.— 
‘‘(1) IN GENERAL.—This section shall not af-
fect the treatment or status of a nonprescription 
drug— 
‘‘(A) that is marketed without an applica-
tion approved under section 505 as of the date 
of the enactment of this section; 
‘‘(B) that is not subject to an order issued 
under this section; and 
‘‘(C) to which paragraphs (1), (2), (3), (4), 
(5), or (6) of subsection (a) do not apply. 
‘‘(2) TREATMENT
OF
PRODUCTS
PREVIOUSLY 
FOUND TO BE SUBJECT TO TIME AND EXTENT RE-
QUIREMENTS.— 
‘‘(A) Notwithstanding subsection (a), a 
drug described in subparagraph (B) may only 
be lawfully marketed, without an application 
approved under section 505, pursuant to an 
order issued under this section. 
‘‘(B) A drug described in this subpara-
graph is a drug which, prior to the date of the 
enactment of this section, the Secretary had de-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00047
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
termined in a proposed or final rule to be ineli-
gible for review under the OTC drug review (as 
such phrase ‘OTC drug review’ was used in sec-
tion 330.14 of title 21, Code of Federal Regula-
tions, as in effect on the day before the date of 
the enactment of this section). 
‘‘(3) PRESERVATION OF AUTHORITY.— 
‘‘(A) Nothing in paragraph (1) shall be 
construed to preclude or limit the applicability 
of any other provision of this Act. 
‘‘(B) Nothing in subsection (a) shall be 
construed to prohibit the Secretary from issuing 
an order under this section finding a drug to be 
not generally recognized as safe and effective 
within the meaning of section 201(p)(1), as the 
Secretary determines appropriate. 
‘‘(n) INAPPLICABILITY OF PAPERWORK REDUCTION 
ACT.—Chapter 35 of title 44, United States Code, shall 
not apply to collections of information made under this 
section. 
‘‘(o) INAPPLICABILITY OF NOTICE AND COMMENT 
RULEMAKING
AND OTHER REQUIREMENTS.—The re-
quirements of subsection (b) shall apply with respect to 
orders issued under this section instead of the require-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00048
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
ments of subchapter II of chapter 5 of title 5, United 
States Code. 
‘‘(p) DEFINITIONS.—In this section: 
‘‘(1) The term ‘nonprescription drug’ refers to 
a drug not subject to the requirements of section 
503(b)(1). 
‘‘(2) The term ‘sponsor’ refers to any person 
marketing, manufacturing, or processing a drug 
that— 
‘‘(A) is listed pursuant to section 510(j); 
and 
‘‘(B) is or will be subject to an administra-
tive order of the Food and Drug Administra-
tion. 
‘‘(3) The term ‘requestor’ refers to any person 
or group of persons marketing, manufacturing, proc-
essing, or developing a drug.’’. 
SEC. 102. MISBRANDING. 
Section 502 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 352) is amended by inserting after para-
graph (dd) the following: 
‘‘(ee) If it is a nonprescription drug that is subject 
to section 505G, not the subject of an application ap-
proved under section 505 or an exemption under section 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00049
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
505(i), and does not comply with the requirements under 
section 505G. 
‘‘(ff) If it is a drug and it was manufactured, pre-
pared, propagated, compounded, or processed in a facility 
for which fees have not been paid as required by section 
744O.’’. 
SEC. 
103. 
DRUGS 
EXCLUDED 
FROM 
THE 
OVER-THE- 
COUNTER DRUG REVIEW. 
(a) IN GENERAL.—Nothing in this Act (or the 
amendments made by this Act) shall apply to any non-
prescription drug which was excluded by the Food and 
Drug Administration from the Over-the-Counter Drug Re-
view in accordance with the statement set out at page 
9466 of volume 37 of the Federal Register, published on 
May 11, 1972. 
(b) RULE OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed to preclude or limit the applica-
bility of any other provision of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 301 et seq.). 
SEC. 104. TREATMENT OF SUNSCREEN INNOVATION ACT. 
(a) REVIEW OF NONPRESCRIPTION SUNSCREEN AC-
TIVE INGREDIENTS.— 
(1) APPLICABILITY
OF
SECTION
505G
FOR 
PENDING SUBMISSIONS.— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00050
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
(A) IN GENERAL.—A sponsor of a non-
prescription sunscreen active ingredient or com-
bination of nonprescription sunscreen active in-
gredients that, as of the date of enactment of 
this Act, is subject to a proposed sunscreen 
order under section 586C of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 360fff–3) 
may elect, by means of giving written notifica-
tion to the Secretary of Health and Human 
Services within 90 calendar days of the enact-
ment of this Act, to transition into the review 
of such ingredient or combination of ingredients 
pursuant to the process set out in section 505G 
of the Federal Food, Drug, and Cosmetic Act, 
as added by section 101 of this Act. 
(B) ELECTION EXERCISED.—Upon receipt 
by the Secretary of Health and Human Services 
of a timely notification under subparagraph 
(A)— 
(i) the proposed sunscreen order in-
volved is deemed to be a request for an 
order under subsection (b) of section 505G 
of the Federal Food, Drug, and Cosmetic 
Act, as added by section 101 of this Act; 
and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00051
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
(ii) such order is deemed to have been 
accepted 
for 
filing 
under 
subsection 
(b)(6)(A)(i) of such section 505G. 
(C) ELECTION NOT EXERCISED.—A spon-
sor of a nonprescription sunscreen active ingre-
dient or combination of nonprescription sun-
screen active ingredients described in subpara-
graph (A) that does not elect for such ingre-
dient or combination of ingredients to be re-
viewed under section 505G of the Federal Food, 
Drug, and Cosmetic Act, as added by section 
101 of this Act, shall continue to have such in-
gredient or combination of ingredients reviewed 
in accordance with section 586C of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 
360fff–3) and may not subsequently elect to 
transition into the review of such ingredient or 
combination of ingredients pursuant to the 
process set out in section 505G of such Act, as 
added by section 101 of this Act. 
(2) DEFINITIONS.—In this subsection, the 
terms ‘‘sponsor’’, ‘‘nonprescription’’, ‘‘sunscreen ac-
tive ingredient’’, and ‘‘proposed sunscreen order’’ 
have the meanings given to those terms in section 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00052
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
586 of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 360fff). 
(b) AMENDMENTS TO SUNSCREEN PROVISIONS.— 
(1) FINAL
SUNSCREEN
ORDERS.—Paragraph 
(3) of section 586C(e) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360fff–3(e)) is amend-
ed to read as follows: 
‘‘(3) RELATIONSHIP TO ORDERS UNDER SEC-
TION 505G.—A final sunscreen order shall be deemed 
to be a final order under section 505G.’’. 
(2) MEETINGS.—Paragraph (7) of section 
586C(b) of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 360fff–3(b)) is amended— 
(A) by striking ‘‘A sponsor may request’’ 
and inserting the following: 
‘‘(A) IN
GENERAL.—A sponsor may re-
quest’’; and 
(B) by adding at the end the following: 
‘‘(B) CONFIDENTIAL MEETINGS.—A spon-
sor may request one or more confidential meet-
ings with respect to a proposed sunscreen order, 
including a letter deemed to be a proposed sun-
screen order under paragraph (3), to discuss 
matters involving confidential commercial infor-
mation or trade secrets. The Secretary shall 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00053
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
convene a confidential meeting with such spon-
sor in a reasonable time period. If a sponsor re-
quests more than one confidential meeting for 
the same proposed sunscreen order, the Sec-
retary may refuse to grant an additional con-
fidential meeting request if the Secretary deter-
mines that such additional confidential meeting 
is not reasonably necessary for the sponsor to 
advance its proposed sunscreen order, or if the 
request for a confidential meeting fails to in-
clude sufficient information upon which to base 
a substantive discussion. The Secretary shall 
publish a post-meeting summary of each con-
fidential meeting under this subparagraph that 
does not disclose confidential commercial infor-
mation or trade secrets.’’. 
(3) SUNSET PROVISION.—Subchapter I of chap-
ter V of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 360fff et seq.) is amended by adding at 
the end the following: 
‘‘SEC. 586H. SUNSET. 
‘‘This subchapter shall cease to be effective at the end 
of fiscal year 2022.’’. 
(c) TREATMENT OF NON-SUNSCREEN TIME AND EX-
TENT APPLICATIONS.— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00054
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
(1) IN GENERAL.—Any application described in 
section 586F of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360fff–6) that was submitted 
to the Secretary of Health and Human Services pur-
suant to section 330.14 of title 21, Code of Federal 
Regulations, as such provisions were in effect imme-
diately prior to the date of enactment date of this 
Act, shall be extinguished as of such date of enact-
ment, subject to paragraph (2). 
(2) ORDER REQUEST.—Nothing in paragraph 
(1) precludes the submission of an order request 
under section 505G(b) of the Federal Food, Drug, 
and Cosmetic Act, as added by section 101 of this 
Act, with respect to a drug that was the subject of 
an application extinguished under paragraph (1). 
SEC. 105. ANNUAL UPDATE TO CONGRESS ON APPRO-
PRIATE PEDIATRIC INDICATION FOR CER-
TAIN OTC COUGH AND COLD DRUGS. 
(a) IN GENERAL.—Subject to subsection (c), the Sec-
retary of Health and Human Services shall, beginning not 
later than one year after the date of enactment of this 
Act, annually submit to the Committee on Energy and 
Commerce of the House of Representatives and the Com-
mittee on Health, Education, Labor, and Pensions of the 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00055
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
Senate a letter describing the progress of the Food and 
Drug Administration— 
(1) in evaluating the cough and cold monograph 
described in subsection (b) with respect to children 
under age 6; and 
(2) as appropriate, revising such cough and cold 
monograph to address such children through the 
order process under section 505G(b) of the Federal 
Food, Drug, and Cosmetic Act, as added by section 
101 of this Act. 
(b) COUGH AND COLD MONOGRAPH DESCRIBED.— 
The cough and cold monograph described in this sub-
section consists of the conditions under which nonprescrip-
tion drugs containing antitussive, expectorant, nasal de-
congestant, or antihistamine active ingredients (or com-
binations thereof) are generally recognized as safe and ef-
fective, as specified in part 341 of title 21, Code of Federal 
Regulations (as in effect immediately prior to the date of 
enactment of this Act), and included in an order deemed 
to be established under section 505G(b) of the Federal 
Food, Drug, and Cosmetic Act, as added by section 101 
of this Act. 
(c) DURATION
OF AUTHORITY.—The requirement 
under subsection (a) shall terminate as of the date of a 
letter submitted by the Secretary of Health and Human 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00056
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
Services pursuant to such subsection in which the Sec-
retary indicates that the Food and Drug Administration 
has completed its evaluation and revised, in a final order, 
as applicable, the cough and cold monograph as described 
in subsection (a)(2). 
TITLE II—USER FEES 
SEC. 201. SHORT TITLE; FINDING. 
(a) SHORT TITLE.—This title may be cited as the 
‘‘Over-the-Counter Monograph User Fee Act of 2018’’. 
(b) FINDING.—The Congress finds that the fees au-
thorized by the amendments made in this title will be dedi-
cated to OTC monograph drug activities, as set forth in 
the goals identified for purposes of part 10 of subchapter 
C of chapter VII of the Federal Food, Drug, and Cosmetic 
Act, in the letters from the Secretary of Health and 
Human Services to the Chairman of the Committee on 
Health, Education, Labor, and Pensions of the Senate and 
the Chairman of the Committee on Energy and Commerce 
of the House of Representatives, as set forth in the Con-
gressional Record. 
SEC. 202. FEES RELATING TO OVER-THE-COUNTER DRUGS. 
Subchapter C of chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is 
amended by inserting after part 9 the following: 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00057
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘PART 10—FEES RELATING TO OVER-THE- 
COUNTER DRUGS 
‘‘SEC. 744N. DEFINITIONS. 
‘‘In this part: 
‘‘(1) The term ‘affiliate’ means a business enti-
ty that has a relationship with a second business en-
tity if, directly or indirectly— 
‘‘(A) one business entity controls, or has 
the power to control, the other business entity; 
or 
‘‘(B) a third party controls, or has power 
to control, both of the business entities. 
‘‘(2) The term ‘contract manufacturing organi-
zation facility’ means an OTC monograph drug facil-
ity where neither the owner of such manufacturing 
facility nor any affiliate of such owner or facility 
sells the OTC monograph drug produced at such fa-
cility directly to wholesalers, retailers, or consumers 
in the United States. 
‘‘(3) The term ‘costs of resources allocated for 
OTC monograph drug activities’ means the expenses 
in connection with OTC monograph drug activities 
for— 
‘‘(A) officers and employees of the Food 
and Drug Administration, contractors of the 
Food and Drug Administration, advisory com-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00058
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
mittees, and costs related to such officers, em-
ployees, and committees and costs related to 
contracts with such contractors; 
‘‘(B) management of information, and the 
acquisition, maintenance, and repair of com-
puter resources; 
‘‘(C) leasing, maintenance, renovation, and 
repair of facilities and acquisition, maintenance, 
and repair of fixtures, furniture, scientific 
equipment, and other necessary materials and 
supplies; and 
‘‘(D) collecting fees under section 744O 
and accounting for resources allocated for OTC 
monograph drug activities. 
‘‘(4) The term ‘FDA establishment identifier’ is 
the unique number automatically generated by Food 
and Drug Administration’s Field Accomplishments 
and Compliance Tracking System (FACTS) (or any 
successor system). 
‘‘(5) The term ‘OTC monograph drug’ means a 
nonprescription drug without an approved new drug 
application which is governed by the provisions of 
section 505G. 
‘‘(6) The term ‘OTC monograph drug activities’ 
means activities of the Secretary associated with 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00059
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
OTC monograph drugs and inspection of facilities 
associated with such products, including the fol-
lowing activities: 
‘‘(A) The activities necessary for review 
and evaluation of OTC monographs and OTC 
monograph order requests, including— 
‘‘(i) orders proposing or finalizing ap-
plicable conditions of use for OTC mono-
graph drugs; 
‘‘(ii) orders affecting status regarding 
general recognition of safety and effective-
ness of an OTC monograph ingredient or 
combination of ingredients under specified 
conditions of use; 
‘‘(iii) all OTC monograph drug devel-
opment and review activities, including 
intraagency collaboration; 
‘‘(iv) regulation and policy develop-
ment activities related to OTC monograph 
drugs; 
‘‘(v) development of product standards 
for products subject to review and evalua-
tion; 
‘‘(vi) meetings referred to in section 
505G(i); 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00060
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(vii) review of labeling prior to 
issuance of orders related to OTC mono-
graph drugs or conditions of use; and 
‘‘(viii) regulatory science activities re-
lated to OTC monograph drugs. 
‘‘(B) Inspections related to OTC mono-
graph drugs. 
‘‘(C) Monitoring of clinical and other re-
search conducted in connection with OTC 
monograph drugs. 
‘‘(D) Safety activities with respect to OTC 
monograph drugs, including— 
‘‘(i) collecting, developing, and review-
ing safety information on OTC monograph 
drugs, including adverse event reports; 
‘‘(ii) developing and using improved 
adverse event data-collection systems, in-
cluding information technology systems; 
and 
‘‘(iii) developing and using improved 
analytical tools to assess potential safety 
risks, including access to external data-
bases. 
‘‘(E) Other activities necessary for imple-
mentation of section 505G. 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00061
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(7) The term ‘OTC monograph order request’ 
means a request for an order submitted under sec-
tion 505G(b)(6). 
‘‘(8) The term ‘Tier 1 OTC monograph order 
request’ means any OTC monograph order request 
not determined to be a Tier 2 OTC monograph 
order request. 
‘‘(9)(A) The term ‘Tier 2 OTC monograph 
order request’ means, subject to subparagraph (B), 
an OTC monograph order request for— 
‘‘(i) the reordering of existing information 
in the drug facts label of an OTC monograph 
drug; 
‘‘(ii) the addition of information to the 
other information section of the drug facts label 
of an OTC monograph drug, as limited by sec-
tion 201.66(c)(7) of title 21, Code of Federal 
Regulations (or any successor regulations); 
‘‘(iii) modification to the directions for use 
section of the drug facts label of an OTC mono-
graph drug, if such changes conform to changes 
made pursuant to section 505G(c)(3)(A); 
‘‘(iv) the standardization of the concentra-
tion or dose of a specific finalized ingredient 
within a particular finalized monograph; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00062
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(v) a change to ingredient nomenclature 
to align with nomenclature of a standards-set-
ting organization; or 
‘‘(vi) addition of an interchangeable term 
in accordance with section 330.1 of title 21, 
Code of Federal Regulations (or any successor 
regulations). 
‘‘(B) The Secretary may, based on program im-
plementation experience or other factors found ap-
propriate by the Secretary, characterize any OTC 
monograph order request as a Tier 2 OTC mono-
graph order request (including recharacterizing a re-
quest from Tier 1 to Tier 2) and publish such deter-
mination in a proposed order issued pursuant to sec-
tion 505G. 
‘‘(10)(A) The term ‘OTC monograph drug facil-
ity’ means a foreign or domestic business or other 
entity that— 
‘‘(i) is— 
‘‘(I) under one management, either di-
rect or indirect; and 
‘‘(II) at one geographic location or ad-
dress engaged in manufacturing or proc-
essing the finished dosage form of an OTC 
monograph drug; 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00063
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) includes a finished dosage form man-
ufacturer facility in a contractual relationship 
with the sponsor of one or more OTC mono-
graph drugs to manufacture or process such 
drugs; and 
‘‘(iii) does not include a business or other 
entity whose only manufacturing or processing 
activities are one or more of the following: pro-
duction of clinical research supplies, or testing. 
‘‘(B) For purposes of subparagraph (A)(i)(II), 
separate buildings or locations within close proximity 
are considered to be at one geographic location or 
address if the activities conducted in such buildings 
or locations are— 
‘‘(i) closely related to the same business 
enterprise; 
‘‘(ii) under the supervision of the same 
local management; and 
‘‘(iii) under a single FDA establishment 
identifier and capable of being inspected by the 
Food and Drug Administration during a single 
inspection. 
‘‘(C) If a business or other entity would meet 
criteria specified in subparagraph (A), but for being 
under multiple management, the business or other 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00064
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
entity is deemed to constitute multiple facilities, one 
per management entity, for purposes of this para-
graph. 
‘‘(11) The term ‘OTC monograph drug meet-
ing’ means any meeting regarding the content of a 
proposed OTC monograph order request. 
‘‘(12) The term ‘person’ includes an affiliate of 
a person. 
‘‘(13) The terms ‘requestor’ and ‘sponsor’ have 
the meanings given such terms in section 505G. 
‘‘SEC. 744O. AUTHORITY TO ASSESS AND USE OTC MONO-
GRAPH FEES. 
‘‘(a) TYPES OF FEES.—Beginning with fiscal year 
2019, the Secretary shall assess and collect fees in accord-
ance with this section as follows: 
‘‘(1) FACILITY FEE.— 
‘‘(A) IN
GENERAL.—Each person that 
owns a facility identified as an OTC monograph 
drug facility on December 31 of the fiscal year 
or at any time during the preceding 12-month 
period shall be assessed an annual fee for each 
such facility as determined under subsection 
(c). 
‘‘(B) EXCEPTIONS.— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00065
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) A fee shall not be assessed under 
subparagraph (A) if the identified OTC 
monograph drug facility has ceased all ac-
tivities related to OTC monograph drugs 
prior to the date specified in subparagraph 
(D)(ii) and has updated its registration to 
reflect such change under the requirements 
for drug establishment registration set 
forth in section 510. 
‘‘(ii) The amount of the fee for a con-
tract manufacturing organization facility 
shall be equal to 2⁄3 the amount of the fee 
for an OTC monograph drug facility that 
is not a contract manufacturing organiza-
tion facility. 
‘‘(C) AMOUNT.—The amount of fees estab-
lished under subparagraph (A) shall be estab-
lished under subsection (c). 
‘‘(D) DUE DATE.— 
‘‘(i) FOR FIRST PROGRAM YEAR.—For 
fiscal year 2019, the facility fees required 
under subparagraph (A) shall be due 45 
calendar days after publication of the Fed-
eral Register notice provided for under 
subsection (c)(4)(A). 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00066
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) SUBSEQUENT
FISCAL
YEARS.— 
For each fiscal year after fiscal year 2019, 
the facility fees required under subpara-
graph (A) shall be due on the later of— 
‘‘(I) the first business day of 
June of such year; or 
‘‘(II) the first business day after 
the enactment of an appropriations 
Act providing for the collection and 
obligation of fees under this section 
for such year. 
‘‘(2) 
OTC 
MONOGRAPH
ORDER
REQUEST 
FEE.— 
‘‘(A) IN GENERAL.—Each person that sub-
mits an OTC monograph order request shall be 
subject to a fee for an OTC monograph order 
request. The amount of such fee shall be— 
‘‘(i) for a Tier 1 OTC monograph 
order request, $500,000, adjusted for in-
flation for the fiscal year (as determined 
under subsection (c)(1)(B)); and 
‘‘(ii) for a Tier 2 OTC monograph 
order request, $100,000 adjusted for infla-
tion for the fiscal year (as determined 
under subsection (c)(1)(B)). 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00067
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(B) DUE
DATE.—The OTC monograph 
order request fees required under subparagraph 
(A) shall be due on the date of submission of 
the OTC monograph order request. 
‘‘(C) EXCEPTION
FOR
CERTAIN
SAFETY 
CHANGES.—A person who is named as the re-
questor in an OTC monograph order shall not 
be subject to a fee under subparagraph (A) if 
the Secretary finds that the OTC monograph 
order request seeks to change the drug facts la-
beling of an OTC monograph drug in a way 
that would add to or strengthen— 
‘‘(i) a contraindication, warning, or 
precaution; 
‘‘(ii) a statement about risk associated 
with misuse or abuse; or 
‘‘(iii) an instruction about dosage and 
administration that is intended to increase 
the safe use of the OTC monograph drug. 
‘‘(D) REFUND OF FEE IF ORDER REQUEST 
IS RECATEGORIZED AS A TIER 2 OTC MONO-
GRAPH ORDER REQUEST.—If the Secretary de-
termines that an OTC monograph request ini-
tially characterized as Tier 1 shall be re-charac-
terized as a Tier 2 OTC monograph order re-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00068
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
quest, and the requestor has paid a Tier 1 fee 
in accordance with subparagraph (A)(i), the 
Secretary shall refund the requestor the dif-
ference between the Tier 1 and Tier 2 fees de-
termined under subparagraphs (A)(i) and 
(A)(ii), respectively. 
‘‘(E) REFUND OF FEE IF ORDER REQUEST 
REFUSED FOR FILING OR WITHDRAWN BEFORE 
FILING.—The Secretary shall refund 75 percent 
of the fee paid under subparagraph (B) for any 
order request which is refused for filing. 
‘‘(F) FEES
FOR
ORDER
REQUESTS
PRE-
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
BEFORE
FILING.—An OTC monograph order 
request that was submitted but was refused for 
filing, or was withdrawn before being accepted 
or refused for filing, shall be subject to the full 
fee under subparagraph (A) upon being resub-
mitted or filed over protest. 
‘‘(G) REFUND OF FEE IF ORDER REQUEST 
WITHDRAWN.—If an order request is withdrawn 
after the order request was filed, the Secretary 
may refund the fee or a portion of the fee if no 
substantial work was performed on the order 
request after the application was filed. The Sec-
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00069
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
retary shall have the sole discretion to refund a 
fee or a portion of the fee under this subpara-
graph. A determination by the Secretary con-
cerning a refund under this subparagraph shall 
not be reviewable. 
‘‘(3) REFUNDS.— 
‘‘(A) IN
GENERAL.—Other than refunds 
provided in subparagraphs (D) through (G) of 
paragraph (2), the Secretary shall not refund 
any fee paid under paragraph (1) except as pro-
vided in subparagraph (B). 
‘‘(B) DISPUTES
CONCERNING
FEES.—To 
qualify for the return of a fee claimed to have 
been paid in error under paragraph (1) or (2), 
a person shall submit to the Secretary a written 
request justifying such return within 180 cal-
endar days after such fee was paid. 
‘‘(4) NOTICE.—Within the timeframe specified 
in subsection (c), the Secretary shall publish in the 
Federal Register the amount of the fees under para-
graph (1) for such fiscal year. 
‘‘(b) FEE REVENUE AMOUNTS.— 
‘‘(1) FISCAL YEAR 2019.—For fiscal year 2019, 
fees under subsection (a)(1) shall be established to 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00070
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
generate a total facility fee revenue amount equal to 
the sum of— 
‘‘(A) the annual base revenue for fiscal 
year 2019 (as determined under paragraph (3); 
‘‘(B) the dollar amount equal to the oper-
ating reserve adjustment for the fiscal year, if 
applicable (as determined under subsection 
(c)(2)); and 
‘‘(C) additional direct cost adjustments (as 
determined under subsection (c)(3)). 
‘‘(2) SUBSEQUENT FISCAL YEARS.—For each of 
the fiscal years 2020 through 2023, fees under sub-
section (a)(1) shall be established to generate a total 
facility fee revenue amount equal to the sum of— 
‘‘(A) the annual base revenue for the fiscal 
year (as determined under paragraph (3)); 
‘‘(B) the dollar amount equal to the infla-
tion adjustment for the fiscal year (as deter-
mined under subsection (c)(1)); 
‘‘(C) the dollar amount equal to the oper-
ating reserve adjustment for the fiscal year, if 
applicable (as determined under subsection 
(c)(2)); 
‘‘(D) additional direct cost adjustments (as 
determined under subsection (c)(3)); and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00071
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(E) additional dollar amounts for each 
fiscal year as follows: 
‘‘(i) $7,000,000 for fiscal year 2020. 
‘‘(ii) $6,000,000 for fiscal year 2021. 
‘‘(iii) $7,000,000 for fiscal year 2022. 
‘‘(iv) $3,000,000 for fiscal year 2023. 
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
of paragraphs (1)(A) and (2)(A), the dollar amount 
of the annual base revenue for a fiscal year shall 
be— 
‘‘(A) for fiscal year 2019, $8,000,000; and 
‘‘(B) for fiscal years 2020 through 2023, 
the dollar amount of the total revenue amount 
established under this subsection for the pre-
vious fiscal year, not including any adjustments 
made under subsection (c)(2) or (c)(3). 
‘‘(c) ADJUSTMENTS; ANNUAL FEE SETTING.— 
‘‘(1) INFLATION ADJUSTMENT.— 
‘‘(A) IN GENERAL.—For purposes of sub-
section (b)(2)(B), the dollar amount of the in-
flation adjustment to the annual base revenue 
for fiscal year 2020 and each subsequent fiscal 
year shall be equal to the product of— 
‘‘(i) such annual base revenue for the 
fiscal year under subsection (b)(2); and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00072
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) the inflation adjustment percent-
age under subparagraph (C). 
‘‘(B) OTC MONOGRAPH ORDER REQUEST 
FEES.—For purposes of subsection (a)(2), the 
dollar amount of the inflation adjustment to the 
fee for OTC monograph order requests for fis-
cal year 2020 and each subsequent fiscal year 
shall be equal to the product of— 
‘‘(i) the applicable fee under sub-
section (a)(2) for the preceding fiscal year; 
and 
‘‘(ii) the inflation adjustment percent-
age under subparagraph (C). 
‘‘(C) INFLATION
ADJUSTMENT
PERCENT-
AGE.—The inflation adjustment percentage 
under this subparagraph for a fiscal year is 
equal to— 
‘‘(i) for each of fiscal years 2020 and 
2021, the average annual percent change 
that occurred in the Consumer Price Index 
for urban consumers (Washington-Balti-
more, DC–MD–VA–WV; Not Seasonally 
Adjusted; All items; Annual Index) for the 
first 3 years of the preceding 4 years of 
available data; and 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00073
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(ii) for each of fiscal years 2022 and 
2023, the sum of— 
‘‘(I) the average annual percent 
change in the cost, per full-time equiv-
alent position of the Food and Drug 
Administration, of all personnel com-
pensation and benefits paid with re-
spect to such positions for the first 3 
years of the preceding 4 fiscal years, 
multiplied by the proportion of per-
sonnel 
compensation 
and 
benefits 
costs to total costs of OTC mono-
graph drug activities for the first 3 
years of the preceding 4 fiscal years; 
and 
‘‘(II) the average annual percent 
change that occurred in the Consumer 
Price Index for urban consumers 
(Washington-Baltimore, DC–MD–VA– 
WV; Not Seasonally Adjusted; All 
items; Annual Index) for the first 3 
years of the preceding 4 years of 
available data multiplied by the pro-
portion of all costs other than per-
sonnel 
compensation 
and 
benefits 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00074
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
costs to total costs of OTC mono-
graph drug activities for the first 3 
years of the preceding 4 fiscal years. 
‘‘(2) OPERATING RESERVE ADJUSTMENT.— 
‘‘(A) IN GENERAL.—For fiscal year 2019 
and subsequent fiscal years, for purposes of 
subsections (b)(1)(B) and (b)(2)(C), the Sec-
retary may, in addition to adjustments under 
paragraph (1), further increase the fee revenue 
and fees if such an adjustment is necessary to 
provide operating reserves of carryover user 
fees for OTC monograph drug activities for not 
more than the number of weeks specified in 
subparagraph (B). 
‘‘(B) NUMBER OF WEEKS.—The number of 
weeks specified in this subparagraph is— 
‘‘(i) 3 weeks for fiscal year 2019; 
‘‘(ii) 7 weeks for fiscal year 2020; 
‘‘(iii) 10 weeks for fiscal year 2021; 
‘‘(iv) 10 weeks for fiscal year 2022; 
and 
‘‘(v) 10 weeks for fiscal year 2023. 
‘‘(C) DECREASE.—If the Secretary has 
carryover balances for such process in excess of 
10 weeks of the operating reserves referred to 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00075
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
in subparagraph (A), the Secretary shall de-
crease the fee revenue and fees referred to in 
such subparagraph to provide for not more than 
10 weeks of such operating reserves. 
‘‘(D) RATIONALE
FOR
ADJUSTMENT.—If 
an adjustment under this paragraph is made, 
the rationale for the amount of the increase or 
decrease (as applicable) in fee revenue and fees 
shall be contained in the annual Federal Reg-
ister notice under paragraph (4) establishing 
fee revenue and fees for the fiscal year involved. 
‘‘(3) 
ADDITIONAL
DIRECT
COST
ADJUST-
MENT.—The Secretary shall, in addition to adjust-
ments under paragraphs (1) and (2), further in-
crease the fee revenue and fees for purposes of sub-
section (b)(2)(D) by an amount equal to— 
‘‘(A) $14,000,000 for fiscal year 2019; 
‘‘(B) $7,000,000 for fiscal year 2020; 
‘‘(C) $4,000,000 for fiscal year 2021; 
‘‘(D) $3,000,000 for fiscal year 2022; and 
‘‘(E) $3,000,000 for fiscal year 2023. 
‘‘(4) ANNUAL FEE SETTING.— 
‘‘(A) FISCAL
YEAR
2019.—The Secretary 
shall, not later than January 31, 2019— 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS
‘‘(i) establish OTC monograph drug 
facility fees for fiscal year 2019 under sub-
section (a), based on the revenue amount 
for such year under subsection (b) and the 
adjustments provided under this sub-
section; and 
‘‘(ii) publish fee revenue, facility fees, 
and OTC monograph order requests in the 
Federal Register. 
‘‘(B) SUBSEQUENT
FISCAL
YEARS.—The 
Secretary shall, not later than January 31 of 
each fiscal year that begins after September 30, 
2019, establish for each such fiscal year, based 
on the revenue amounts under subsection (b) 
and the adjustments provided under this sub-
section— 
‘‘(i) OTC monograph drug facility fees 
under subsection (a)(1); 
‘‘(ii) OTC monograph order request 
fees under subsection (a)(2); and 
‘‘(iii) 
publish 
such 
fee 
revenue 
amounts, facility fees, and OTC mono-
graph order request fees in the Federal 
Register. 
VerDate Sep 11 2014 
23:08 Apr 03, 2018
Jkt 079200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6201
E:\BILLS\H5333.IH
H5333
amozie on DSK30RV082PROD with BILLS